Dosiomics-Based Detection of Dose Distribution Variations in Helical Tomotherapy for Prostate Cancer Patients: Influence of Treatment Plan Parameters Publisher Pubmed



Mirzaeiyan M^{1, 2} ; Akhavan A³ ; Hemati S³ ; Etehadtavakol M¹ ; Amouheidari A⁴ ; Adibi A⁵ ; Khanahmad H⁶ ; Sharifonnasabi Z⁷ ; Shokrani P¹ Show Affiliations
Source: Physical and Engineering Sciences in Medicine Published:2024

Abstract

The stability of dosiomics features (DFs) and dose-volume histogram (DVH) parameters for detecting disparities in helical tomotherapy planned dose distributions was assessed. Treatment plans of 18 prostate patients were recalculated using the followings: field width (WF) (2.5 vs. 5), pitch factor (PF) (0.433 vs. 0.444), and modulation factor (MF) (2.5 vs. 3). From each of the eight plans per patient, ninety-three original and 744 wavelet-based DFs were extracted, using 3D-Slicer software, across six regions including: target volume (PTV), pelvic lymph nodes (PTV-LN), PTV + PTV-LN (PTV-All), one cm rind around PTV-All (PTV-Ring), rectum, and bladder. For the resulting DFs and DVH parameters, the coefficient of variation (CV) was calculated, and using hierarchical clustering, the features were classified into low/high variability. The significance of parameters on instability was analyzed by a three-way analysis of variance. All DF’s were stable in PTV, PTV-LN, and PTV-Ring (average CV (CV¯) ≤ 0.36). Only one feature in the bladder (CV¯ = 0.9), rectum (CV¯ = 0.4), and PTV-All (CV¯ = 0.37) were considered unstable due to change in MF in the bladder and WF in the PTV-All. The value of CV¯ for the wavelet features was much higher than that for the original features. Out of 225 unstable wavelet features, 84 features had CV¯ ≥ 1. The CVs for all the DVHs remained very small (CV¯< 0.06). This study highlights that the sensitivity of DFs to changes in tomotherapy planning parameters is influenced by the region and the DFs, particularly wavelet features, surpassing the effectiveness of DVHs. © Australasian College of Physical Scientists and Engineers in Medicine 2024.